Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability

Cell Death and Differentiation

Volumn 10, Issue 4, 2003, Pages 461-467

  Mrozek A ^a   Petrowsky, H ^c   Sturm, I ^a   Kraus, J ^b   Hermann, S ^a   Hauptmann, S ^b   Lorenz, M ^c   Dorken B ^a   Daniel, P T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Bax; DNA mismatch repair (MMR) deficiency; Gastric carcinoma; Microsatellite instability (MSI); Mutation; p53; Prognosis

Indexed keywords

DNA; PROTEIN BAX; PROTEIN P53;

ADULT; AGED; APOPTOSIS; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DISEASE SEVERITY; DNA DAMAGE; FEMALE; FRAMESHIFT MUTATION; GASTRECTOMY; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH CARCINOMA; TUMOR CELL;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DNA REPAIR; HUMANS; MICROSATELLITE REPEATS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038075337     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401193     Document Type: Review

References (42)

1. Stadtlander CT and Waterbor JW (1999) Molecular epidemiology pathogenesis and prevention of gastric cancer. Carcinogenesis 20: 2195-2208
2. Neugut AI, Hayek M and Howe G (1996) Epidemiology of gastric cancer. Semin. Oncol. 23: 281-291
3. Black RJ, Bray F, Ferlay J and Parkin DM (1997) Cancer incidence and mortality in the European union: cancer registry data and estimates of national incidence for 1990. Eur. J. Cancer. 33: 1075-1107
4. Fuchs CS and Mayer RJ (1995) Gastric carcinoma. N. Engl. J. Med. 333: 32-41
5. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD and Dörken B (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60: 854-859
6. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD and Dörken B (1996) Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in scid mice. J. Clin. Invest. 97: 2651-2659
7. Bosanquet, Sturm I, Wieder T, Essmann F, Margaret I, Bosanquet M, Head DJ, Dörken B and Daniel PT (2001) Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 16: 1035-1044
8. Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B and Daniel PT (2002) Adenovirus-mediated overexpression of p14arf induces p53 and bax-independent apoptosis. Oncogene 21: 3149-3161
9. von Haefen C, Wieder T, Gillissen B, Stärck L, Graupner V, Dörken B and Daniel PT (2002) Ceramide induces mitochondrial activation and apoptosis via a bax-dependent pathway in human carcinoma cells. Oncogene 21: 4009-4019
10. Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT (2002) The apoptosis promoting bcl-2 homologues bak and nbk/bik overcome drug resistance in mdr-1-negative and mdr-1 overexpressing breast cancer cell lines. Oncogene 21: 227-238
11. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC (1995) Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55: 4471-4478
12. Tai YT, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA (1998) Bax protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 16: 2583-2590
13. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B and Daniel PT (2002) Analysis of p53/bax in primary colorectal carcinoma: low bax protein expression is a negative prognostic factor in uicc stage I tumors. Int. J. Cancer. 99: 589-596
14. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B and Daniel PT (1999) Analysis of the p53/bax pathway in colorectal cancer: Low bax is a negative prognostic factor in patients with resected liver metastases. J. Clin. Oncol. 17: 1364-1374
15. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B and Daniel PT (2001) Analysis of p53/bax/p16ink4a/cdkn2 in esophageal squamous cell carcinoma: high bax and p16ink4a/cdkn2 identifies patients with good prognosis. J. Clin. Oncol. 19: 2272-2281
16. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM and Büchler MW (1998) Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421
17. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B and Daniel PT (2000) Relapse in childhood acute lymphoblastic leukemia is associated with decrease of bax/bcl-2-ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14: 1606-1613
18. Miyashita. T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
19. Benchimol S (2001) P53-dependent pathways of apoptosis. Cell Death Differ. 8: 1049-1051
20. Wang JY (2001) DNA damage and apoptosis. Cell Death Differ. 8: 1047-1048
21. Puthalakath H and Strasser A (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of B4-only proteins. Cell Death Differ. 9: 505-512
22. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B and Daniel PT (2001) Bax expression in benign and malignant thyroid tumors: dysregulation of wild type p53 is associated with a high bax and p21 expression in thyroid carcinoma. Int. J. Cancer 92: 805-811
23. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M (1997) Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969
24. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück H-J, Wolff G, Dörken B and Daniel PT (2000) Impaired bax protein expression in breast cancer: mutational analysis of the bax and the p53 gene. Int. J. Cancer 87: 517-521
25. Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K and Perucho M (1999) Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 116: 1348-1357
26. dos Santos NR, Seruca R, Constancia M, Seixas M and Sobrinho-Simoes M (1996) Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 110: 38-44
27. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S (1998) A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58: 5248-5257
28. Iacopetta BJ, Soong R, House AK and Hamelin R (1999) Gastric carcinomas with microsatellite instability: clinical features and mutations to the tgf-beta type ii receptor, igfii receptor, and bax genes. J. Pathol. 187: 428-432
29. Stone JG, Tomlinson IP and Houlston RS (2000) Optimising methods for determining rer status in colorectal cancers. Cancer Lett. 149: 15-20
30. Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, Sobrinho-Simoes M, Lothe RA, Gleeson CM, Russell SE, Muzeau F, Flejou JF, Hoang-Xuan K, Lidereau R, Thomas G and Hamelin R (1998) Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 21: 101-107
31. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR and Shibata D (1994) P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res. 54: 4750-4755
32. Yamamoto H, Itoh F, Fukushima H, Adachi Y, Itoh H, Hinoda Y and Imai K (1999) Frequent bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J. Exp. Clin. Cancer Res. 18: 103-106
33. Perucho M (1999) Correspondence re: C.R. Boland et al., a National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res, 58: 5248-5257, 1998. Cancer Res. 59: 249-256
34. Gomyo Y, Osaki M, Kaibara N and Ito H (1996) Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (fish) and pcr-sscp. Int. J. Cancer 66: 594-599
35. Shiao YH, Rugge M, Correa P, Lehmann HP and Scheer WD (1994) P53 alteration in gastric precancerous lesions. Am. J. Pathol. 144: 511-517
36. Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G and Hamelin R (1996) Inverse correlation between rer+ status and p53 mutation in colorectal cancer cell lines. Oncogene 13; 2727-2730
37. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, Kishi N, Iwama T, Mori T, Koike M, Ushio K, Chiba M, Nomizu S, Konishi F, Utsunomiya J and Miyaki M (1996) Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111: 307-317
38. Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ and Chen KM (1998) Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br. J. Surg. 85: 1138-1142
39. Allgayer H, Heiss MM and Schildberg FW (1997) Prognostic factors in gastric cancer. Br. J. Surg. 84: 1651-1664
40. Lim BH, Soong R, Grieu F, Robbins PD, House AK and Iacopetta BJ (1996) P53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int. J. Cancer 69: 200-204
41. Victorzon M, Nordling S, Haglund C, Lundin J and Roberts PJ (1996) Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur. J. Cancer 32A: 215-220
42. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R and Solcia E (1995) P53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol. Biomarkers Prev. 4: 223-231